Evidence map›Paper›PMID 41858162›Full record

SynthesisBJU international2026

Intravesical therapy for recurrent urinary tract infection: a systematic review and meta-analysis.

Matthew Kwon, Asaad Ahmad, Natalie Lott, Alison Blatt

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matthew KwonDepartment of Urology, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.ORCID 0000-0002-8798-8802
Asaad AhmadUniversity of Newcastle, Callaghan, New South Wales, Australia.
Natalie LottDepartment of Surgical Research, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
Alison BlattDepartment of Urology, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo undertake a systematic review and meta-analysis to evaluate the efficacy, safety, and clinical applicability of intravesical instillations for preventing recurrent urinary tract infections (rUTIs).

methodsPubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, and Web of Science were searched from January 2000 to April 2025 for randomised and observational studies of intravesical instillations in rUTI treatment. The primary outcome was UTI recurrence, expressed as incidence rate ratio (IRR) or risk ratio (RR). Random-effects meta-analyses were performed for three intervention families: aminoglycosides, hyaluronic acid (HA) monotherapy, and HA with chondroitin sulphate (HA + CS) combined therapy. Subgroup analyses examined population type and antibiotic used; sensitivity analyses included leave-one-out re-estimation. Other agents were narratively synthesised.

resultsTotal of 25 studies were included. Aminoglycoside instillations produced a marked reduction in recurrence (pooled IRR 0.23, 95% confidence interval [CI] 0.15-0.37; P < 0.001), with consistent benefit across neurogenic and non-neurogenic populations and across gentamicin and amikacin. HA monotherapy was also effective (pooled RR 0.15, 95% CI 0.05-0.43; P = 0.011), although heterogeneity was high. HA + CS combined therapy showed favourable results in individual studies but an imprecise pooled effect (RR 0.41, 95% CI 0.04-4.77; P = 0.465). Narrative evidence for heparin, povidone-iodine and fosfomycin suggested potential benefit, but methods and outcome definitions were inconsistent. Serum aminoglycoside levels were undetectable where measured, and adverse events were mild and infrequent.

conclusionIntravesical instillations appear safe and effective for preventing rUTIs in select patients. The strongest evidence supports aminoglycosides while HA offers a non-antibiotic alternative. HA + CS requires further study. Larger, high-quality randomised trials with standardised outcomes are needed to optimise protocols and patient selection.

Indexed as

AminoglycosidesAnti-Bacterial AgentsHyaluronic AcidUrinary Tract InfectionsAdministration, IntravesicalChondroitin SulfatesDrug Therapy, CombinationHumansRecurrenceAminoglycosidesAnti-Bacterial AgentsChondroitin SulfatesHyaluronic Acidadministration, intravesicalantibioticmeta‐analysisprophylaxisurinary tract infection

Identifiers

PMID41858162
PMCPMC13244587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.